Al B. Benson, MD, FACP, FASCO, professor of medicine and director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center, stresses the importance of approaching difficult hepatobiliary cancer settings with a multifaceted care team.
Al B. Benson, MD, FACP, FASCO, professor of medicine and director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center, stresses the importance of approaching difficult hepatobiliary cancer settings with a multifaceted care team.
Transcript
Can you discuss the importance of a multidisciplinary approach in hepatobiliary cancers?
These are diseases that are very challenging, particularly with HCC, where people typically have 2 diseases we're dealing with: the primary tumor, as well as the underlying liver disease, including cirrhosis, so they do represent challenging patients. But nonetheless, it's encouraging that we have been able to develop trials looking at first-line, second-line, even third-line interventions for patients and identifying a longer list of agents that can produce benefit.
We also emphasize that we're promoting the multidisciplinary approach for the care of these patients, because for HCC, for example, we need to evaluate to determine if a patient is a transplant patient. Is the patient potentially resectable? Or would a liver-directed therapy be more appropriate? Or is this a situation where systemic therapy is the more ultimate approach? Or perhaps there are people where we would give systemic therapy as well as liver-directed therapies. So to make these types of decisions, including review for eligibility of clinical trials, we need to encourage upfront multidisciplinary discussions. And this also brings in other individuals—for example, radiologists to make sure that appropriate imaging has been obtained, as well as hepatologists, because many of the these individuals require the skill sets of hepatologists to more effectively manage patients. I think what we've seen is, the more often we have these multidisciplinary approaches, not only do we make sure we're maximizing the potential interventions for patients, but we think that this improves longer term outcomes for these individuals.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer
January 15th 2025The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Patient-Reported QOL Outcomes of Initial CLL Treatments: ASH 2024
January 8th 2025Quality-of-life (QOL) outcomes vary widely for patients receiving first-line treatment for chronic lymphocytic leukemia (CLL), according to research presented at the 2024 American Society of Hematology (ASH) meeting.
Read More